coin-img-ETHETH-4.47%coin-img-BTCBTC-2.83%coin-img-SOLSOL-4.47%coin-img-XRPXRP-4.70%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-9.20%coin-img-TRXTRX-1.36%coin-img-ETHETH-4.47%coin-img-BTCBTC-2.83%coin-img-SOLSOL-4.47%coin-img-XRPXRP-4.70%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-9.20%coin-img-TRXTRX-1.36%coin-img-ETHETH-4.47%coin-img-BTCBTC-2.83%coin-img-SOLSOL-4.47%coin-img-XRPXRP-4.70%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-9.20%coin-img-TRXTRX-1.36%coin-img-ETHETH-4.47%coin-img-BTCBTC-2.83%coin-img-SOLSOL-4.47%coin-img-XRPXRP-4.70%coin-img-UBOXUBOX+0.00%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE-9.20%coin-img-TRXTRX-1.36%
user-avatar
The Economic Times

Sakar Healthcare reports Rs 10.28 crore Q1 FY2026-27 net profit, revenue rises to Rs 72.97 crore

AI Market Summary
Sakar Healthcare reported strong Q1 FY27 results, with net profit up 120% YoY and operating revenue up 38%, highlighting accelerating commercialization and export momentum in its oncology franchise. Management cited 65+ oncology product contracts executed and 50+ ongoing commercial discussions, reinforcing visibility on pipeline-to-revenue conversion. The update is supportive for the company's listed equity but is unlikely to be broadly market-moving.
Impact level
● Low
Affected assets
ON/USDT+25.25%
AI Insight · ON/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Sakar Healthcare reported Q1 FY2026-27 net profit of Rs 10.28 crore, up 120% year on year. Revenue from operations rose 38% to Rs 72.97 crore. The company said it executed more than 65 oncology product contracts during the quarter and has over 50 commercial discussions currently underway. The results were notably stronger than a year earlier, reflecting progress in commercialising its oncology-focused portfolio and benefiting its listed stock ONUS.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.